FOSUN PHARMA (02196) climbed nearly 5% during early trading hours. As of press time, the stock was up 3.95% to HK$22.08, with trading volume reaching HK$107 million.

On the news front, FOSUN PHARMA released its 2025 interim results on August 26. The company reported revenue of approximately 19.514 billion yuan, representing a 4.63% year-over-year decline. Net profit attributable to shareholders reached approximately 1.702 billion yuan, marking a significant 38.96% year-over-year increase. Basic earnings per share stood at 0.64 yuan. Notably, innovative drug revenue demonstrated steady growth, exceeding 4.3 billion yuan and increasing 14.26% compared to the same period last year.

The company attributed the profit increase primarily to gains from divesting its remaining stake in United Family Healthcare and other non-core assets.

On the same day, FOSUN PHARMA announced that its controlling subsidiary, Fosun Pharma Industry, has granted Sitala development, manufacturing, and commercialization rights for FXS6837 and products containing this active ingredient within the licensed territory (global scope excluding China, including Hong Kong, Macau, and Taiwan regions) and field (diagnosis and treatment of human and animal diseases).

Under the licensing arrangement, Fosun Pharma Industry (or its designated affiliates) can acquire Sitala shares worth $5 million at zero cost. The company stated that this collaboration will help accelerate the global clinical development and commercialization process of the licensed products while continuing to expand the group's overseas presence in innovative products.